businesspress24.com - RXT 110 INC. Announces the Resignation of Donald Meade as Director
 

RXT 110 INC. Announces the Resignation of Donald Meade as Director

ID: 1032086

(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 08/19/11 -- RXT 110 INC. (CNSX: RXT) (the "Company") announced today that Mr. Donald Meade has resigned as a director of the Company.

About RXT 110 Inc.

RXT 110 Inc.'s line of retail anti-microbial products will effectively kill mould, bacteria and fungi on contact and prevent re-growth. These products address the demand created by the mounting health and environmental concerns. Mould can affect the immune system, nervous system, liver, kidneys, blood and cause brain damage.

RXT will also manufacture and distribute RXT 110, an anti-microbial filler. Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attracting mold. Annual global revenue in the calcium carbonate filler industry approximates 140 billion dollars. RXT 110 Inc. will produce anti-microbial filler that performs 'filling' and 'bulking' functions like calcium carbonate. RXT 110 does not attract moisture and consequently mold infestation. RXT filler with its anti-microbial high ph core in individual particles enhances commercial product life and eradicates a broad spectrum of known bacteria, fungi, algae and other micro - organisms by suppression of their reproduction.

On behalf of the Board of Directors of RXT 110 Inc.

Bruce Lewis, Chairman

The CNSX has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release. Neither the CNSX nor its Regulation Services Provider (as such term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
RXT 110 Inc.
Bruce Lewis
Chairman




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Cytokinetics Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet
No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 19.08.2011 - 08:35 Uhr
Sprache: Deutsch
News-ID 1032086
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 155 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"RXT 110 INC. Announces the Resignation of Donald Meade as Director
"
steht unter der journalistisch-redaktionellen Verantwortung von

RXT 110 Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von RXT 110 Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 73


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.